See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Donald Trump
India Economy
Baseball
Social Media
Tariffs
Basketball
Artificial Intelligence
European Union
Easter
Trade War
US Economy
Democratic Party
Published • loading... • Updated

Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan – DIR HONGKONG

Summary by dirhongkong.com
TOKYO, Mar 5, 2025 – (JCN Newswire via SeaPRwire.com) – Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN® Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. Sato Pharmaceutical and Eisai have concluded a new …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
dirhongkong.comdirhongkong.com

Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan – DIR HONGKONG

TOKYO, Mar 5, 2025 – (JCN Newswire via SeaPRwire.com) – Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN® Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. Sato Pharmaceutical and Eisai have concluded a new …

Read Full Article
eastmud.comeastmud.com

Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan – EastMud

TOKYO, Mar 5, 2025 – (JCN Newswire via SeaPRwire.com) – Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN® Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025. Sato Pharmaceutical and Eisai have concluded a new …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

eastmud.com broke the news in on Wednesday, March 5, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Tokyo, Japan

Tokyo, Japan

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal